Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIRCH: GS-5245 in High-Risk Outpatients With COVID-19
jRCT2031220645Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Mar 2023
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing GS-5245 with Placebo (2 arms). Primary endpoint: Proportion of COVID-19 related hospitalization or all-cause death by Day 29. Started Mar 2023; status: completed.
02
Drugs
obeldesivir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031220645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220645.